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Introduction
Nitrous oxide (N2O) interferes with vitamin B12 and folate 
metabolism. This impairs the production of methionine (from 
homocysteine), used to form tetrahydrofolate and thymidine 
during DNA synthesis. N2O increases postoperative homocysteine 
levels. Chronic hyperhomocysteinaemia is associated with 
cardiovascular disease, and we have demonstrated that N2O 
leads to postoperative endothelial dysfunction.1
In our previous trial, ENIGMA, 2 050 patients were studied, 
and some serious adverse effects identified,2 but these 
were secondary end-points, and it has been argued that the 
differences in inspired oxygen concentration could explain some 
or all of the findings. In addition, most patients were not at risk 
of coronary artery disease, so we could not reliably assess serious 
cardiac complications. 
We conducted an international, randomised, assessor-blinded 
trial in patients with known or suspected coronary artery disease 
undergoing major non-cardiac surgery.3 Patients were randomly 
assigned to receive a general anaesthetic, with or without N2O. 
The primary outcome measure was a composite of death and 
cardiovascular complications (non-fatal myocardial infarction, a 
stroke, pulmonary embolism or cardiac arrest) within 30 days of 
surgery. Secondary end-points included surgical site infection, 
severe nausea and vomiting, and hospital length of stay. 
Of 10 102 eligible patients, 7 112 consenting patients were 
enrolled. Three thousand five hundred and forty-three were 
assigned to the N2O group and 3 569 to the non-N2O group. The 
primary outcome occurred in 283 (8.1%) patients in the N2O 
group and in 296 (8.4%) patients in the non-N2O group (relative 
risk 0.96, 95% confidence interval: 0.82-1.13; p-value 0.64). 
Surgical site infection occurred in 9.2% and 8.9% of patients 
(p-value 0.85), and severe nausea and vomiting in 15% and 11% 
of patients (p-value < 0.001) in the non-N2O and N2O groups, 
respectively. The median hospital length of stay was 6.1 days 
(interquartile range 3.3-10 days) in both groups (p-value 0.69). 
The outcomes are shown in Table I.
N2O did not increase the risk of death and cardiovascular 
complications or surgical site infection in patients undergoing 
major non-cardiac surgery. It is possible that N2O may reduce the 
risk of persistent pain after surgery.4
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Table I: ENIGMA-II outcomes
Outcomes N2O, n (%)
(n = 3 543)
Non-N2O, n (%)
(n = 3 569)
RR, n (%) 
(95% CI)
p-value
One-degree end-point: death, MI, a stroke, cardiac arrest or PE 283 (8.1) 296 (8.4) 0.96 (0.82-1.13) 0.64
Death 42 (1.2) 57 (1.6) 0.74 (0.50-1.11) 0.14
MI 215 (6.2) 219 (6.2) 0.99 (0.82-1.19) 0.91
A stroke 26 (0.7) 19 (0.6) 1.38 (0.76-2.49) 0.29
Cardiac arrest 15 (0.4) 19 (0.5) 0.80 (0.40-1.56) 0.51
PE 18 (0.5) 22 (0.6) 0.82 (0.4-1.53) 0.54
CI: confidence interval, MI: myocardial infarction, N20: nitrous oxide PE: pulmonary embolism, RR: relative risk
